Patent landscape highlighting therapeutic implications of peptides targeting myristoylated alanine-rich protein kinase-C substrate (MARCKS)

References

• Aslam N, Alvi F. Protein kinase C life cycle: explained through systems biology approach. Front Physiol. 2022;13:818688. doi: 10.3389/fphys.2022.818688
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C as a tumor suppressor. Semin Cancer Biol. 2018;48:18–26. doi: 10.1016/j.semcancer.2017.04.017
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Membrane phospholipid degradation and protein kinase C for cell signalling. Neurosci Res. 1992;15(1–2):3–5. doi: 10.1016/0168-0102(92)90013-3
   PubMed Web of Science ®Google Scholar
• Kikkawa U. The story of PKC: A discovery marked by unexpected twists and turns. IUBMB Life. 2019;71(6):697–705. doi: 10.1002/iub.1963
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012;11(12):937–957. doi: 10.1038/nrd3871
   PubMed Web of Science ®Google Scholar
• Iyer DN, Faruq O, Zhang L, et al. Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies. Biomark Res. 2021;9(1):34. doi: 10.1186/s40364-021-00286-9
   PubMed Web of Science ®Google Scholar
• Fong LWR, Yang DC, Chen CH. Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers. Cancer Metastasis Rev. 2017;36(4):737–747. doi: 10.1007/s10555-017-9709-6
   PubMed Web of Science ®Google Scholar
• Mohapatra P, Yadav V, Toftdahl M, et al. Wnt5A-Induced activation of the protein kinase C substrate MARCKS is required for melanoma cell invasion. Cancers (Basel). 2020;12(2):346. doi: 10.3390/cancers12020346
   PubMed Web of Science ®Google Scholar
• Iioka H, Ueno N, Kinoshita N. Essential role of MARCKS in cortical actin dynamics during gastrulation movements. J Cell Bio. 2004;164(2):169–174. doi: 10.1083/jcb.200310027
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Shiraishi M, Fukami K, et al. MARCKS regulates lamellipodia formation induced by IGF-I via association with PIP2 and beta-actin at membrane microdomains. J Cell Physiol. 2009;220(3):748–755. doi: 10.1002/jcp.21822
   PubMed Web of Science ®Google Scholar
• Eckert RE, Neuder LE, Park J, et al. Myristoylated alanine-rich C-kinase substrate (MARCKS) protein regulation of human neutrophil migration. Am J Respir Cell Mol Biol. 2010;42(5):586–594. doi: 10.1165/rcmb.2008-0394OC
   PubMed Web of Science ®Google Scholar
• Brudvig JJ, Weimer JM. X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease. Front Cell Neurosci. 2015;9:407. doi: 10.3389/fncel.2015.00407
   PubMed Web of Science ®Google Scholar
• Sheats MK, Sung EJ, Adler KB, et al. In Vitro Neutrophil migration requires protein kinase C-Delta (δ-PKC)-Mediated Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) phosphorylation. Inflammation. 2015;38(3):1126–1141. doi: 10.1007/s10753-014-0078-9
   PubMed Web of Science ®Google Scholar
• Amri ME, Fitzgerald U, Schlosser G. MARCKS and MARCKS-like proteins in development and regeneration. J Biomed Sci. 2018;25(1):43. doi: 10.1186/s12929-018-0445-1
   PubMedGoogle Scholar
• Yadav V, Jobe N, Mehdawi L, et al. Targeting oncogenic WNT signalling with WNT signalling-derived peptides. Handb Exp Pharmacol. 2021;269:279–303.
   PubMedGoogle Scholar
• Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. doi: 10.1038/s41392-022-00904-4
   PubMed Web of Science ®Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707. doi: 10.1016/j.bmc.2017.06.052
   PubMed Web of Science ®Google Scholar
• Parrasia S, Szabò I, Zoratti M, et al. Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges. Mol Pharm. 2022;19(11):3700–3729. doi: 10.1021/acs.molpharmaceut.2c00523
   PubMedGoogle Scholar
• Yadav V, Misra R. A review emphasizing on utility of heptad repeat sequence as a tool to design pharmacologically safe peptide-based antibiotics. Biochimie. 2021;191:126–139. doi: 10.1016/j.biochi.2021.09.001
   PubMed Web of Science ®Google Scholar
• Muttenthaler M, King GF, Adams DJ, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325. doi: 10.1038/s41573-020-00135-8
   PubMed Web of Science ®Google Scholar
• Chiu C-L, Zhao H, Chen C-H, et al. The role of MARCKS in metastasis and treatment resistance of solid tumors. Cancers (Basel). 2022;14(19):4925. doi: 10.3390/cancers14194925
   PubMed Web of Science ®Google Scholar
• Yin Q, Fang S, Park J, et al. An inhaled inhibitor of myristoylated alanine-rich C kinase substrate reverses LPS-Induced acute lung injury in mice. Am J Respir Cell Mol Biol. 2016;55(5):617–622. doi: 10.1165/rcmb.2016-0236RC
   PubMed Web of Science ®Google Scholar
• Agrawal A, Rengarajan S, Adler KB, et al. Inhibition of mucin secretion with MARCKS-related peptide improves airway obstruction in a mouse model of asthma. J App Physiol. 2007;102(1):399–405. doi: 10.1152/japplphysiol.00630.2006
   PubMed Web of Science ®Google Scholar
• Chen CH, Statt S, Chiu CL, et al. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am J Respir Crit Care Med. 2014;190(10):1127–1138. doi: 10.1164/rccm.201408-1505OC
   PubMed Web of Science ®Google Scholar
• Liu J, Chen SJ, Hsu SW, et al. MARCKS cooperates with NKAP to activate NF-Kb signaling in smoke-related lung cancer. Theranostics. 2021;11(9):4122–4136. doi: 10.7150/thno.53558
   PubMed Web of Science ®Google Scholar
• Corradin S, Ransijn A, Corradin G, et al. Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J. 2002;367(Pt 3):761–769. doi: 10.1042/bj20020386
   PubMedGoogle Scholar
• Green TD, Crews AL, Park J, et al. Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein? Biochim Biophys Acta. 2011;1810(11):1110–1113. doi: 10.1016/j.bbagen.2011.01.009
   PubMed Web of Science ®Google Scholar
• Park J, Fang S, Crews AL, et al. MARCKS regulation of mucin secretion by airway epithelium in vitro: interaction with chaperones. Am J Respir Cell Mol Biol. 2008;39(1):68–76. doi: 10.1165/rcmb.2007-0139OC
   PubMed Web of Science ®Google Scholar
• Fang S, Crews AL, Chen W, et al. MARCKS and HSP70 interactions regulate mucin secretion by human airway epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol. 2013;304(8):L511–8. doi: 10.1152/ajplung.00337.2012
   PubMed Web of Science ®Google Scholar
• Yu QS, Feng WQ, Shi LL, et al. Integrated analysis of cortex single-cell transcriptome and serum proteome reveals the novel biomarkers in alzheimer’s disease. Brain Sci. 2022;12(8):1022. doi: 10.3390/brainsci12081022
   PubMed Web of Science ®Google Scholar
• Li Y, Martin LD, Spizz G, et al. MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem. 2001;276(44):40982–40990. doi: 10.1074/jbc.M105614200
   PubMed Web of Science ®Google Scholar
• Takashi S, Park J, Fang S, et al. A peptide against the N-terminus of myristoylated alanine-rich C kinase substrate inhibits degranulation of human leukocytes in vitro. Am J Respir Cell Mol Biol. 2006;34(6):647–652. doi: 10.1165/rcmb.2006-0030RC
   PubMed Web of Science ®Google Scholar
• Lee SM, Suk K, Lee WH. Myristoylated alanine-rich C kinase substrate (MARCKS) regulates the expression of proinflammatory cytokines in macrophages through activation of p38/JNK MAPK and NF-κB. Cell Immunol. 2015;296(2):115–121. doi: 10.1016/j.cellimm.2015.04.004
   PubMed Web of Science ®Google Scholar
• Biomarck Pharmaceuticals Ltd. US20210260154A1. 2021.
   Google Scholar
• University of California. US20200206308A1. 2021
   Google Scholar
• Biomarck Pharmaceuticals Ltd. US20220305078A1. 2021
   Google Scholar
• Li C, Xia R, Xue H, et al. Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma. Oncol Lett. 2018;16(4):5498–5504. doi: 10.3892/ol.2018.9311
   PubMed Web of Science ®Google Scholar
• Manai M, ELBini-Dhouib I, Finetti P, et al. MARCKS as a potential therapeutic target in inflammatory breast cancer. Cells. 2022;11(18):2926. doi: 10.3390/cells11182926
   PubMed Web of Science ®Google Scholar
• Hanada S, Kakehashi A, Nishiyama N, et al. Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomark. 2013;13(4):289–298. doi: 10.3233/CBM-130354
   PubMed Web of Science ®Google Scholar
• Doghri R, Manai M, Finetti P, et al. Stromal expression of MARCKS protein in ovarian carcinomas has unfavorable prognostic value. Int J Mol Sci. 2017;19(1):41. doi: 10.3390/ijms19010041
   PubMed Web of Science ®Google Scholar
• Micallef J, Taccone M, Mukherjee J, et al. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 2009;69(19):7548–7556. doi: 10.1158/0008-5472.CAN-08-4783
   PubMed Web of Science ®Google Scholar
• Jarboe JS, Anderson JC, Duarte CW, et al. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res. 2012;18(11):3030–3041. doi: 10.1158/1078-0432.CCR-11-3091
   PubMed Web of Science ®Google Scholar
• Rao G, Pierobon M, Kim IK, et al. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep. 2017;7(1):7066. doi: 10.1038/s41598-017-06128-9
   PubMedGoogle Scholar
• Quan R, Ning Z, Wang Y, et al. Prognostic Value of Upregulation of Myristoylated Alanine-Rich C-Kinase Substrate in Gastric Cancer. Med Sci Monit. 2019;25:279–287. doi: 10.12659/MSM.913558
   PubMed Web of Science ®Google Scholar
• Lu H, Zhao R, Qin Q, et al. MARCKS is a New Prognostic Biomarker in Hepatocellular Carcinoma. Int J Gen Med. 2023;16:1603–1619. doi: 10.2147/IJGM.S408651
   PubMed Web of Science ®Google Scholar
• Button E, Shapland C, Lawson D. Actin, its associated proteins and metastasis. Cell Motil Cytoskeleton. 1995;30(4):247–251. doi: 10.1002/cm.970300402
   PubMed Web of Science ®Google Scholar
• Manai M, Thomassin-Piana J, Gamoudi A, et al. MARCKS protein overexpression in inflammatory breast cancer. Oncotarget. 2017;8(4):6246–6257. doi: 10.18632/oncotarget.14057
   PubMedGoogle Scholar
• Manai M, Abdeljaoued S, Goucha A, et al. MARCKS protein overexpression is associated with poor prognosis in male breast cancer. Cancer Biomark. 2019;26(4):513–522. doi: 10.3233/CBM-190637
   PubMed Web of Science ®Google Scholar
• Cho SJ, La M, Ahn JK, et al. Tob-mediated cross-talk between MARCKS phosphorylation and ErbB-2 activation. Biochem Biophys Res Commun. 2001;283(2):273–277. doi: 10.1006/bbrc.2001.4773
   PubMed Web of Science ®Google Scholar
• Chen C-H, Fong LWR, Yu E, et al. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. Oncogene. 2017;36(25):3588–3598. doi: 10.1038/onc.2016.510
   PubMed Web of Science ®Google Scholar
• Techasen A, Loilome W, Namwat N, et al. Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci. 2010;101(3):658–665. doi: 10.1111/j.1349-7006.2009.01427.x
   PubMed Web of Science ®Google Scholar
• Rombouts K, Carloni V, Mello T, et al. Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Lett. 2013;333(2):244–252. doi: 10.1016/j.canlet.2013.01.040
   PubMed Web of Science ®Google Scholar
• Song J, Wang Q, Luo Y, et al. MiR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS. Int J Clin Exp Pathol. 2015;8(10):12728–12737.
   PubMed Web of Science ®Google Scholar
• Yadav V, Jobe N, Satapathy SR, et al. Increased MARCKS activity in BRAF inhibitor-resistant melanoma cells is essential for their enhanced metastatic behavior independent of elevated WNT5A and IL-6 signaling. Cancers (Basel). 2022;14(24):6077. doi: 10.3390/cancers14246077
   PubMed Web of Science ®Google Scholar
• Chen CH, Thai P, Yoneda K, et al. A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene. 2014;33(28):3696–3706. doi: 10.1038/onc.2013.336
   PubMed Web of Science ®Google Scholar
• Rohrbach TD, Shah N, Jackson WP, et al. The effector domain of MARCKS is a nuclear localization signal that regulates cellular PIP2 levels and nuclear PIP2 localization. Plos One. 2015;10(10):e0140870. doi: 10.1371/journal.pone.0140870
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Bivona TG. Polytherapy and targeted cancer drug resistance. Trends Cancer. 2019;5(3):170–182. doi: 10.1016/j.trecan.2019.02.003
   PubMed Web of Science ®Google Scholar
• Dianat-Moghadam H, Heidarifard M, Jahanban-Esfahlan R, et al. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. J Control Release. 2018;288:62–83. doi: 10.1016/j.jconrel.2018.08.043
   PubMed Web of Science ®Google Scholar
• Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721–8743. doi: 10.7150/thno.41648
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014;13(7):497–512. doi: 10.1038/nrd4253
   PubMed Web of Science ®Google Scholar
• Browne BC, Hochgraffe F, Wu J, et al. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS J. 2013;280(21):5237–5257. doi: 10.1111/febs.12441
   PubMed Web of Science ®Google Scholar
• Chen CH, Cheng CT, Yuan Y, et al. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget. 2015;6(17):15194–15208. doi: 10.18632/oncotarget.3827
   PubMedGoogle Scholar
• Kim YE, Kim EK, Song MJ, et al. SILAC-Based quantitative proteomic analysis of oxaliplatin-resistant pancreatic cancer cells. Cancers (Basel). 2021;13(4):724. doi: 10.3390/cancers13040724
   PubMed Web of Science ®Google Scholar
• Muguruma Y, Yahata T, Warita T, et al. Jagged1-induced notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J. 2017;7(12):650. doi: 10.1038/s41408-017-0001-3
   PubMedGoogle Scholar
• Gerber JM, Gucwa JL, Esopi D, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4(5):715–728. doi: 10.18632/oncotarget.990
   PubMed Web of Science ®Google Scholar
• Brandi J, Pozza ED, Dando I, et al. Secretome protein signature of human pancreatic cancer stem-like cells. J Proteomics. 2016;136:1–12. doi: 10.1016/j.jprot.2016.01.017
   PubMed Web of Science ®Google Scholar
• Wenzel T, Büch T, Urban N, et al. Restoration of MARCKS enhances chemosensitivity in cancer. J Cancer Res Clin Oncol. 2020;146(4):843–858. doi: 10.1007/s00432-020-03149-2
   PubMed Web of Science ®Google Scholar
• North Carolina State University, Biomarck Pharmaceuticals Ltd. US11466054B2. 2022.
   Google Scholar
• University of California. US10189881B2. 2019.
   Google Scholar
• Kawano T, Inokuchi J, Eto M, et al. Activators and inhibitors of Protein Kinase C (PKC): their applications in clinical trials. Pharmaceutics. 2021;13(11):1748. doi: 10.3390/pharmaceutics13111748
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer. 2007;7(7):554–562. doi: 10.1038/nrc2168
   PubMed Web of Science ®Google Scholar
• Eustace NJ, Anderson JC, Warram JM, et al. A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma. Oncogene. 2020;39(46):6961–6974. doi: 10.1038/s41388-020-01511-9
   PubMed Web of Science ®Google Scholar
• North Carolina State University, Biomarck Pharmaceuticals Ltd. WO2011060349A1. 2011.
   Google Scholar
• de la Torre BG, Albericio F. The pharmaceutical industry in 2021. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2022;27(3):1075. doi: 10.3390/molecules27031075
   PubMed Web of Science ®Google Scholar